{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T19:05:55Z","timestamp":1783105555239,"version":"3.54.6"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Follicular lymphoma (FL) is a common type of non-Hodgkin lymphoma that is incurable but often follows an indolent course. While survival is improving thanks to advances in diagnosis, supportive care, and new therapies, understanding outcomes and their impact on overall survival is still limited. There are few studies on FL in Brazil, so this study aims to evaluate the patient\u2019s profile, morbidity and mortality treated by the Brazilian national health service (SUS) and evaluate risk factors associated with treatment failure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is a nationwide 16\u00a0years cohort with patients that underwent chemotherapy in the SUS (2000\u20132015). The Kaplan-Meier method was used to estimate survival until treatment failure, and the Cox proportional hazards model was used to evaluate risk factors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The cohort included 10,009 patients and survival rates were 73.3%, 45.3%, and 30.7% for the first, fifth and 10th year respectively. The median overall survival was approximately 4.1\u00a0years. The most used regimen was CHOP (13%), followed by CVP (9.7%) and R-CHOP (3.3%). Four hundred and ninety-eight patients (4.9%) used rituximab-containing regimens. Univariate analysis indicated worse survival rates for male patients, those over 65\u00a0years of age, clinical stage III or IV and those using non-rituximab-containing regimens. The health technology performance assessment related to oncology schemes for FL suggests that rituximab-based regimens has shown best survival probability (0.52 CI 0.39\u20130.69) in 78\u00a0months of follow up with a HR 1.5 times better than other schemes (HR 0.67; CI 0.55\u20130.81).<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>In light of the substantial advancements achieved by the SUS, there is a need for CONITEC to expedite decision-making processes in order to enhance patients access to new oncology drugs. This should be done while upholding health technology assessment standards. Timely integration and sufficient funding for oncology services have the potential to save lives, especially when compared to the treatments available within SUS at that time.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1414244","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T08:31:47Z","timestamp":1736497907000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Survival analysis of a 16-year cohort of follicular lymphoma patients receiving systemic treatment in Brazil"],"prefix":"10.3389","volume":"15","author":[{"given":"Pamela Santos","family":"Azevedo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Zuppo Laper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah Marta do Santos","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriano de Paula","family":"Sabino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina Morgado","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabela Cristina Menezes de","family":"Freitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wallace Mateus","family":"Prata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari\u00e2ngela Leal","family":"Cherchiglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"\u00c1lvares-Teodoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco de Assis","family":"Acurcio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusto Afonso Guerra","family":"J\u00fanior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1080\/03007995.2020.1722945","article-title":"Comparative persistence of anti-tumor necrosis factor therapy in ankylosing spondylitis patients: a multicenter international study","volume":"36","author":"Acurcio","year":"2020","journal-title":"Curr. Med. Res. Opin."},{"key":"B2","year":"1998"},{"key":"B3","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S0140-6736(16)32407-2","article-title":"Non-Hodgkin lymphoma","volume":"390","author":"Armitage","year":"2017","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41408-020-00340-z","article-title":"Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups","volume":"10","author":"Batlevi","year":"2020","journal-title":"Blood Cancer J."},{"key":"B5","article-title":"SECRETARIA DE ATEN\u00c7\u00c3O \u00c0 SA\u00daDE (SAS). Protocolos cl\u00ednicos e diretrizes terap\u00eauticas em oncologia","year":"2014","journal-title":"Minist\u00e9rio Sa\u00fade"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1590\/1980-549720220006.supl.1","article-title":"Socioeconomic development and colorectal cancer mortality in a state of the Brazilian Legal Amazon from 2005 to 2016","volume":"25","author":"Cal\u00f3","year":"2022","journal-title":"Rev. Bras. Epidemiol."},{"key":"B7","article-title":"Secretaria Executiva M da S. DATASUS","year":""},{"key":"B8","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41408-021-00574-5","article-title":"Risk of second primary malignancies in patients with follicular lymphoma: a population-based study in The Netherlands, 1989-2018","volume":"11","author":"Dinnessen","year":"2021","journal-title":"Blood Cancer J."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1200\/JCO.2012.45.0866","article-title":"R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the fondazione italiana linfomi","volume":"31","author":"Federico","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1017\/S0266462317000423","article-title":"HEALTH TECHNOLOGY PERFORMANCE ASSESSMENT: REAL-WORLD EVIDENCE FOR PUBLIC HEALTHCARE SUSTAINABILITY","volume":"33","author":"Guerra-J\u00fanior","year":"2017","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an east German study group hematology and oncology study","volume":"25","author":"Herold","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","article-title":"Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"B14","article-title":"Estimativa | 2023 Incid\u00eancia de c\u00e2ncer no Brasil","year":"2023"},{"key":"B15","doi-asserted-by":"publisher","first-page":"446","DOI":"10.23889\/ijpds.v3i1.446","article-title":"Building the national database of health centred on the individual: administrative and epidemiological record linkage - Brazil, 2000-2015","volume":"3","author":"Junior","year":"2018","journal-title":"Int. J. Popul. Data Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/leu.2014.251","article-title":"Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry Study","volume":"29","author":"Junl\u00e9n","year":"2015","journal-title":"Leukemia"},{"key":"B17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s40273-017-0579-0","article-title":"The assessment for disinvestment of intramuscular interferon beta for relapsing-remitting multiple sclerosis in Brazil","volume":"36","author":"Lemos","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4373","DOI":"10.1038\/s41598-020-61378-4","article-title":"A clinico-genotypic prognostic index for de novo composite diffuse large B-cell lymphoma arising from follicular lymphoma in asian patients treated in the rituximab era","volume":"10","author":"Lim","year":"2020","journal-title":"Sci. Rep."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"B20","unstructured":"Minist\u00e9rio da Sa\u00fade. PORTARIA No 1051, DE 10 DE OUTUBRO DE 2014\n          \n          \n          2014"},{"key":"B21","unstructured":"Rituximabe para o tratamento de linfoma n\u00e3o-Hodgkin de c\u00e9lulas B, folicular\n          \n          \n          2013"},{"key":"B22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41408-020-0299-0","article-title":"Patterns of change in treatment, response, and outcome in patients with follicular lymphoma over the last four decades: a single-center experience","volume":"10","author":"Mozas","year":"2020","journal-title":"Blood Cancer J."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1200\/GO.20.00099","article-title":"Panorama of gynecologic cancer in Brazil","volume":"6","author":"Paulino","year":"2020","journal-title":"JCO Glob. Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e2100265","DOI":"10.1200\/GO.21.00265","article-title":"Clinical outcomes of patients with B-cell non-hodgkin lymphoma in real-world settings: findings from the hemato-oncology Latin America observational registry study","volume":"8","author":"Pavlovsky","year":"2022","journal-title":"JCO Glob. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1200\/JCO.2016.70.8651","article-title":"Thirty-month complete response as a surrogate end point in first-line follicular lymphoma therapy: an individual patient-level analysis of multiple randomized trials","volume":"35","author":"Shi","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"5019","DOI":"10.1200\/JCO.2005.04.503","article-title":"Improved survival of follicular lymphoma patients in the United States","volume":"23","author":"Swenson","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1182\/blood-2013-03-491514","article-title":"Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience","volume":"122","author":"Tan","year":"2013","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/cncr.20773","article-title":"Richter syndrome: biology, incidence, and therapeutic strategies","volume":"103","author":"Tsimberidou","year":"2005","journal-title":"Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13045-021-01139-6","article-title":"Clinical features and outcomes of 1845 patients with follicular lymphoma: a real-world multicenter experience in China","volume":"14","author":"Zha","year":"2021","journal-title":"J. Hematol. Oncol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1414244\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T08:31:55Z","timestamp":1736497915000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1414244\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,10]]},"references-count":30,"alternative-id":["10.3389\/fphar.2024.1414244"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1414244","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,10]]},"article-number":"1414244"}}